Add BrightSurf on Google Email

Science News Archive April 2014 - Page 19


Page 19 of 32

Young dads at high risk of depression, too

Depressive symptoms increased by 68% in young fathers over the first five years of fatherhood. Early intervention is crucial to help young men transition through this critical period and mitigate the detrimental effects on their children's language, reading, and behavior development.

SourceNorthwestern University·JournalPEDIATRICS·DateApr 14, 2014

Gene linked to pediatric kidney cancer suggests new strategies for kidney regeneration

Researchers found that nearly one-third of pediatric kidney cancer cases are linked to the Lin28 gene, which holds promise for regenerating damaged kidneys. The study's findings suggest that controlled expression of Lin28 can promote kidney development and may lead to new therapeutic targets for treating Wilms tumors.

SourceBoston Children's Hospital·JournalCurrent Opinion in Genetics & Development·DateApr 13, 2014

Glasses strong as steel: A fast way to find the best

Scientists at Yale University have developed a faster way to identify and characterize complex alloys known as bulk metallic glasses (BMGs), which are stronger than steel. The new method allows researchers to screen about 3,000 alloys per day, significantly reducing the time needed for discovery.

SourceYale University·JournalNature Materials·DateApr 13, 2014

Hereditary trauma

Scientists have discovered a link between hereditary trauma and short RNA molecules, which can be passed down from one generation to the next. The research found that traumatic stress alters the expression of microRNAs in mice, leading to behavioral symptoms such as depression and altered metabolism.

SourceETH Zurich·JournalNature Neuroscience·DateApr 13, 2014

Three new studies help clarify optimal use of combination therapy in chronic hepatitis B patients

Studies show sequential combination therapy with peginterferon and nucleoside analogues results in high complete response and HBsAg loss rates. Baseline HBsAg level and rate of decline during treatment predict treatment response. Adding peginterferon to entecavir enhances response rates, viral decline, and facilitates discontinuation.